Other headlinesiCAD hosts webinars on prostate cancer
Chip for interventional imaging enters market
Chip technology that promises to extend the product lifecycle, while reducing the size and energy consumption of interventional radiology equipment is now on the market. The chip, a field-programmable gate array (FPGA), incorporates ContextVision’s GOPView iRVPlus. This software is designed specifically to process fluoroscopy images, such as those accompanying angioplasty or stent replacement, during which real-time images are used to guide catheters. It was unveiled at RSNA 2008.
iCAD hosts webinars on prostate cancer
Computer-aided detection specialist iCAD is reaching out to a broad array of specialists involved in the diagnosis and treatment of prostate cancer, in an effort to highlight advanced image analysis and workflow solutions developed by the company. Two webinars, entitled “Prostate MRI – A Paradigm Shift in Prostate Cancer Diagnosis and Management” and scheduled for Oct. 15 and Nov. 10, will focus on how MR combines with iCAD’s quantitative image analysis software VividLook to support improved prostate cancer management. The company hopes to interest radiologists, urologists, oncologists, radiation oncologists, surgeons, technologists and other referring physicians in the course, which will include clinical case reviews. These reviews will demonstrate prostate cancer detection in patients with previously negative prostate biopsy and rising PSA values, as well as the use of dynamic contrast enhanced MR and CAD to monitor prostate cancer response to radiation therapy.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.